We report a lymphoma patient with profound B-cell deficiency after chemotherapy combined with anti-CD20 antibody successfully treated with remdesivir and convalescent plasma for prolonged SARS-CoV-2 infection. Viral clearance was likely attributed to the robust expansion and activation of TCR Vβ2 CD8+ cytotoxic T cells and CD16 + CD56- NK cells. This is the first presentation of TCR-specific T cell oligoclonal response in COVID-19. Our study suggests that B-cell depleted patients may effectively respond to anti-SARS-CoV-2 treatment when NK and antigen-specific Tc cell response is induced.
All Keywords
【저자키워드】 COVID-19, oligoclonal T cell response, TCR Vβ repertoire, CD8+ cytotoxic T cells, natural killer cells (NK cells), 【초록키워드】 Treatment, convalescent plasma, antibody, T cells, SARS-COV-2 infection, NK cells, Remdesivir, anti-SARS-CoV-2, viral clearance, Antigen, Chemotherapy, T cell, Cytotoxic T cells, lymphoma, Patient, TCR, anti-CD20, B-cell, CD16, Cytotoxic T cell, deficiency, Activation, CD56, CD8+, clearance, Cell, robust, treated, respond, 【제목키워드】 SARS-CoV-2, persistent, report, cytotoxic, Depleted,
【저자키워드】 COVID-19, oligoclonal T cell response, TCR Vβ repertoire, CD8+ cytotoxic T cells, natural killer cells (NK cells), 【초록키워드】 Treatment, convalescent plasma, antibody, T cells, SARS-COV-2 infection, NK cells, Remdesivir, anti-SARS-CoV-2, viral clearance, Antigen, Chemotherapy, T cell, Cytotoxic T cells, lymphoma, Patient, TCR, anti-CD20, B-cell, CD16, Cytotoxic T cell, deficiency, Activation, CD56, CD8+, clearance, Cell, robust, treated, respond, 【제목키워드】 SARS-CoV-2, persistent, report, cytotoxic, Depleted,
우리는 장기간 SARS-CoV-2 감염에 대해 렘데시비르 및 회복기 혈장으로 성공적으로 치료된 항-CD20 항체와 결합된 화학요법 후 심각한 B 세포 결핍증이 있는 림프종 환자를 보고합니다. 바이러스 제거는 TCR Vβ2 CD8+ 세포독성 T 세포 및 CD16 + CD56-NK 세포의 강력한 확장 및 활성화에 기인한 것 같습니다. 이것은 COVID-19에서 TCR 특이적 T 세포 올리고클론 반응의 첫 번째 발표입니다. 우리의 연구는 NK 및 항원 특이적 Tc 세포 반응이 유도될 때 B 세포 고갈 환자가 항 SARS-CoV-2 치료에 효과적으로 반응할 수 있음을 시사합니다.